Just three months after winning a landmark Supreme Court victory in a prescription-drug data-mining case, Netherlands-based Wolters Kluwer has announced it will exit the business of providing marketing and analytics to the pharmaceutical industry while remaining a player elsewhere in health information.
Wolters Kluwer to sell pharmaceutical unit
"The planned divestment of the pharma business will focus our health division on taking full advantage of our leading positions in professional information and clinical decision support solutions, one of the fastest growing areas of health, to deliver enhanced value to our stakeholders,” Wolters Kluwer CEO and board Chairwoman Nancy McKinstry said in an e-mailed announcement. No timetable for the divestment was announced.
According to the announcement, on the block as part of the company's pharmaceutical business unit includes is the Adis stable of peer-reviewed pharmaceutical journals and the Source line of prescription drug data-mining tools and analytics services.
Wolters Kluwer's Source Healthcare Analytics subsidiary was a party in Sorrell v. IMS Health, which the U.S. Supreme Court decided in June in favor of pharmaceutical data miners who had sought to have a Vermont law curbing the use of provider-identified patient prescription data for use in drug marketing struck down.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.